TIDMAGL
RNS Number : 9140F
Angle PLC
17 November 2015
For immediate release 17 November 2015
ANGLE plc
("ANGLE" or "the Company")
CANCER RESEARCH UK MANCHESTER INSTITUTE REPORTS LUNG CANCER CTC
ENRICHMENT USING PARSORTIX
ANGLE's Parsortix system "... offers a unique combination of
features making it suitable for routine clinical analysis of
patient blood samples"
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is delighted to announce that Cancer Research UK
Manchester Institute (CRUK MI) has published highly encouraging
results from its work in lung cancer patients using ANGLE's
Parsortix system in the Royal Society of Chemistry's publication,
Analyst.
Analyst publishes peer-reviewed analytical and bioanalytical
research that reports premier fundamental discoveries and
inventions, and the applications of those discoveries. The
publication is available at
http://www.angleplc.com/the-parsortix-system/download-files/
Lung cancer is the most common cancer in the world. More than
1.8 million cases of lung cancer were recorded in 2012, accounting
for around 13 per cent of all new cancer cases (Source: World
Cancer Research Fund International). Effective treatment for lung
cancer is dependent on the cancer status which is determined
through biopsy. However, where traditional solid biopsies are
invasive and can harm the patient, liquid biopsies offer a
non-surgical, patient-friendly alternative.
Ged Brady, Deputy and Genomics Leader within the Clinical &
Experimental Pharmacology group at Cancer Research UK Manchester
Institute, commented:
"The Parsortix system has a unique combination of features
making it suitable for routine clinical analysis of patient blood
samples. We have now incorporated the Parsortix workflow into
multiple clinical trials and have been accumulating many hundreds
of stored enriched samples that will be of immense value in our
future CTC studies."
ANGLE's Founder and Chief Executive, Andrew Newland, added:
"This is our second peer-reviewed publication in a scientific
journal and adds to the growing body of published evidence of
Parsortix's performance as a liquid biopsy. The success in pilot
studies in harvesting CTCs from 100% of small-cell lung cancer
patients comes after similar performance with 100% of prostate,
breast and ovarian cancer types. We believe Parsortix is changing
the paradigm for CTC capture and harvest for liquid biopsy and will
change CTC molecular analysis from being a theoretical but
impractical goal to being simple and effective in hospital
laboratories all over the world. The prospect of deployment of our
repeatable, non-invasive liquid biopsy in the treatment of lung
cancer patients is exciting and has the potential to make a major
impact in improving future cancer care."
CRUK MI undertook a clinical head-to-head comparison of
Parsortix with CellSearch, the only CTC (circulating tumour cell)
technology currently approved by the FDA (1) and thus the current
"gold standard" in CTC detection. The comparison was undertaken
with small cell lung cancer (SCLC), a particularly aggressive form
of lung cancer, as it is known to be a cancer where CellSearch is
considered to perform well as a result of large numbers of EpCAM
+ve CTCs. In this pilot study:
-- Paired blood samples were taken from 12 patients with SCLC
for enrichment and enumerated by both CellSearch and Parsortix
-- Parsortix captured and harvested for analysis 20 or more CTCs in all 12 samples (100%)
-- CellSearch identified CTCs in 10 out of 12 samples but, of
these, three samples contained fewer than five CTCs
-- At the five cell cut-off, CellSearch only managed to isolate
CTCs for 7/12 patients (58%) compared to Parsortix's 12/12 patients
(100%)
A further important differentiation of the Parsortix system is
that CRUK MI adopted a workflow that first removed plasma from the
blood sample, before running the cell component of the sample on
Parsortix. In all 11 samples where it was undertaken, significant
levels of cell-free DNA (cfDNA) could be purified. CRUK MI thus
demonstrated that using Parsortix a single blood sample can be used
for both cfDNA and CTC analysis. There are many research groups
focused on cfDNA analysis. CRUK MI's work in this area clearly
demonstrates Parsortix's capability to work in tandem with these
approaches to provide additional clinical information, for example
RNA and protein expression.
ANGLE considers the findings reported in the Analyst
publication, which, in addition to the clinical work on lung
cancer, reports on extensive work that CRUK MI have undertaken on
the system since 2012, to be of great importance in demonstrating
the potential value of the Parsortix in future cancer care. Key
points extracted from the publication's conclusion section
include:
"In summary, the approach we have described offers a unique
combination of features making it suitable for routine clinical
analysis of patient blood samples.
Firstly, the epitope independent CTC enrichment approach we have
devised is compatible with whole blood stabilisation reagents
suitable for at least four days at room temperature.
Secondly, CTC enrichment takes place in a simple plug and play
device that remains sealed throughout the enrichment step and the
enriched cells are eluted directly into a collection tube for
further analysis.
Thirdly, the approach delivers both plasma for cfDNA analysis
and cells for CTC enrichment, enabling direct comparisons of
molecular readouts from both cfDNA and CTC.
Fourthly, enriched CTC samples can be banked for later analysis
providing the much needed flexibility often required to select
relevant subsets of samples as well as analytical approaches
appropriate to specific clinical trials and biological
questions.
Finally, our initial clinical results with SCLC patient blood
samples clearly demonstrate that the CTC enrichment process we have
developed identifies subsets of CTCs not readily detected by
epitope dependent technologies thereby facilitating more extensive
CTC analysis which may help determine the underlying patient cancer
status providing the potential for improving patient outcomes."
(1) The CellSearch system is the only FDA approved circulating
tumour cell system. It is approved for CTC enumeration only, for a
limited number of cancers and not for CTC harvesting for analysis.
The CellSearch system captures cells based on their expression of
the cell surface marker EpCAM.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Russell Kerr, Olly Baxendale (Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, Canada, China and Australia
and three extensive families of patents are being progressed
worldwide. The system is based on a microfluidic device that
captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These Key Opinion Leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESUNSWRVOAAAAA
(END) Dow Jones Newswires
November 17, 2015 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024